454 related articles for article (PubMed ID: 29093229)
1. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.
Eliana F; Suwondo P; Asmarinah A; Harahap A; Djauzi S; Prihartono J; Pemayun TGD
Acta Med Indones; 2017 Jul; 49(3):195-204. PubMed ID: 29093229
[TBL] [Abstract][Full Text] [Related]
2. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
Yin X; Latif R; Bahn R; Tomer Y; Davies TF
Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
[TBL] [Abstract][Full Text] [Related]
3. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
4. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease.
Gu LQ; Zhu W; Zhao SX; Zhao L; Zhang MJ; Cui B; Song HD; Ning G; Zhao YJ
Clin Endocrinol (Oxf); 2010 Feb; 72(2):248-55. PubMed ID: 19438904
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
6. Synergistic combined effect between CD40-1C>T and CTLA-4+6230G>A polymorphisms in Graves' disease.
Chen X; Hu Z; Li W; Wu P; Liu M; Bao L; Wu M; Fang S; Xiong W; Chen M; Wu G
Gene; 2015 Aug; 567(2):154-8. PubMed ID: 25936345
[TBL] [Abstract][Full Text] [Related]
7. Association of polymorphism at position 49 in exon 1 of the cytotoxic T-lymphocyte-associated factor 4 gene with Graves' disease refractory to medical treatment, but not with amiodarone-associated thyroid dysfunction.
Kimura H; Kato Y; Shimizu S; Takano K; Sato K
Thyroid; 2009 Sep; 19(9):975-81. PubMed ID: 19731979
[TBL] [Abstract][Full Text] [Related]
8. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
Izumi Y; Takeoka K; Amino N
Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
[TBL] [Abstract][Full Text] [Related]
11. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease.
Kim KW; Park YJ; Kim TY; Park DJ; Park KS; Cho BY
Thyroid; 2007 Dec; 17(12):1229-34. PubMed ID: 17949264
[TBL] [Abstract][Full Text] [Related]
12. TSHR Gene Polymorphisms in the Enhancer Regions Are Most Strongly Associated with the Development of Graves' Disease, Especially Intractable Disease, and of Hashimoto's Disease.
Fujii A; Inoue N; Watanabe M; Kawakami C; Hidaka Y; Hayashizaki Y; Iwatani Y
Thyroid; 2017 Jan; 27(1):111-119. PubMed ID: 27762730
[TBL] [Abstract][Full Text] [Related]
13. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.
Bufalo NE; Dos Santos RB; Marcello MA; Piai RP; Secolin R; Romaldini JH; Ward LS
J Endocrinol Invest; 2015 May; 38(5):555-61. PubMed ID: 25543543
[TBL] [Abstract][Full Text] [Related]
14. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
15. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal.
Wang PW; Liu RT; Juo SH; Wang ST; Hu YH; Hsieh CJ; Chen MH; Chen IY; Wu CL
J Clin Endocrinol Metab; 2004 Jan; 89(1):169-73. PubMed ID: 14715845
[TBL] [Abstract][Full Text] [Related]
17. Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis.
Gong J; Jiang SJ; Wang DK; Dong H; Chen G; Fang K; Cui JR; Lu FE
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):473-479. PubMed ID: 27465319
[TBL] [Abstract][Full Text] [Related]
18. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
[TBL] [Abstract][Full Text] [Related]
19. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
20. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
